Literature DB >> 9595218

Acute coronary syndromes in the United States and United Kingdom: a comparison of approaches. The Antithrombotic Therapy in Acute Coronary Syndromes Research Group.

P C Adams1, J S Skinner, M Cohen, R McBride, V Fuster.   

Abstract

BACKGROUND: Patients with coronary artery disease are managed differently in different countries. HYPOTHESIS: These variations in patient management may affect clinical outcome, a possibility that should be taken into consideration in multicenter studies.
METHODS: In a binational, 3 months study of antithrombotic treatment of patients with unstable angina and non-Q-wave infarction (ATACS), we compared the experience in the four enrollment centers in the United States (US) with the three centers in the United Kingdom (UK). The 59 US patients and the 299 UK patients were similar with regard to age, rates of prior revascularization, prior positive exercise tests, medication use, and aspirin use.
RESULTS: US patients were more commonly women (45 vs. 28%), diabetic (30 vs. 4%), or hypertensive (52 vs. 31%), and had a prior coronary angiogram (30 vs. 18%). After enrollment, coronary angiography was performed more frequently in the US than in the UK (61 vs. 22%). Although the distribution of coronary disease was similar, revascularization without recurrent angina (19 vs. 4%, p < 0.001), or following recurrent angina (8 vs. 3%), was significantly more frequent in the US. Combined primary end points (recurrent angina, myocardial infarction, or death) did not differ between US (29%) and UK (25%) patients.
CONCLUSION: Therefore, international studies of acute coronary disease need to account for different treatments in different countries. These differences, in the small ATACS study, did not have a major impact on the composite primary outcome variables.

Entities:  

Mesh:

Year:  1998        PMID: 9595218      PMCID: PMC6656248          DOI: 10.1002/clc.4960210510

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  14 in total

1.  Waiting for coronary artery bypass surgery: population-based study of 8517 consecutive patients in Ontario, Canada. The Steering Committee of the Adult Cardiac Care Network of Ontario.

Authors:  C D Naylor; K Sykora; S B Jaglal; S Jefferson
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

2.  Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study.

Authors:  R J Luchi; S M Scott; R H Deupree
Journal:  N Engl J Med       Date:  1987-04-16       Impact factor: 91.245

3.  Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfarin in aspirin users with unstable angina or non-Q wave myocardial infarction at rest. The Antithrombotic Therapy in Acute Coronary Syndromes Research Group.

Authors:  M Cohen; G Parry; P C Adams; J Xiong; D Chamberlain; I Wieczorek; K A Fox; R Kronmal; V Fuster
Journal:  Eur Heart J       Date:  1994-09       Impact factor: 29.983

4.  Diagnosis and treatment of coronary disease: comparison of doctors' attitudes in the USA and the UK.

Authors:  R H Brook; J B Kosecoff; R E Park; M R Chassin; C M Winslow; J R Hampton
Journal:  Lancet       Date:  1988-04-02       Impact factor: 79.321

5.  Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group.

Authors: 
Journal:  Lancet       Date:  1990-10-06       Impact factor: 79.321

6.  Comparison of early invasive and conservative treatments in patients with anterior wall non-Q-wave acute myocardial infarction.

Authors:  C S Lotan; M Jonas; Y Rozenman; M Mosseri; J Benhorin; L Rudnik; Y Hasin; M S Gotsman
Journal:  Am J Cardiol       Date:  1995-08-15       Impact factor: 2.778

7.  Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.

Authors:  L Pilote; R M Califf; S Sapp; D P Miller; D B Mark; W D Weaver; J M Gore; P W Armstrong; E M Ohman; E J Topol
Journal:  N Engl J Med       Date:  1995-08-31       Impact factor: 91.245

8.  Variation in the use of cardiac procedures after acute myocardial infarction.

Authors:  E Guadagnoli; P J Hauptman; J Z Ayanian; C L Pashos; B J McNeil; P D Cleary
Journal:  N Engl J Med       Date:  1995-08-31       Impact factor: 91.245

9.  Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.

Authors:  F Van de Werf; E J Topol; K L Lee; L H Woodlief; C B Granger; P W Armstrong; G I Barbash; J R Hampton; A Guerci; R J Simes
Journal:  JAMA       Date:  1995 May 24-31       Impact factor: 56.272

10.  Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden.

Authors:  L C Wallentin
Journal:  J Am Coll Cardiol       Date:  1991-12       Impact factor: 24.094

View more
  3 in total

1.  Practice patterns and attitudes about treating abnormal uterine bleeding: a national survey of obstetricians and gynecologists.

Authors:  Kristen A Matteson; Britta L Anderson; Stephanie B Pinto; Vrishali Lopes; Jay Schulkin; Melissa A Clark
Journal:  Am J Obstet Gynecol       Date:  2011-05-14       Impact factor: 8.661

2.  Trends in PCI volume after negative results from the COURAGE trial.

Authors:  David H Howard; Yu-Chu Shen
Journal:  Health Serv Res       Date:  2013-07-05       Impact factor: 3.402

Review 3.  Inequalities in care in patients with acute myocardial infarction.

Authors:  Shabnam Rashid; Alexander Simms; Phillip Batin; John Kurian; Chris P Gale
Journal:  World J Cardiol       Date:  2015-12-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.